Artelo Biosciences (NASDAQ:ARTL) Price Target Cut to $18.00 by Analysts at D. Boral Capital

Artelo Biosciences (NASDAQ:ARTL) had its price objective trimmed by D. Boral Capital from $20.00 to $18.00 in a report released on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, D Boral Capital upgraded shares of Artelo Biosciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 8th. Two investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Strong Buy” and a consensus price target of $24.00.

Artelo Biosciences Price Performance

ARTL opened at $9.93 on Monday. Artelo Biosciences has a 12 month low of $4.92 and a 12 month high of $28.60. The stock has a market capitalization of $6.95 million, a price-to-earnings ratio of -0.55 and a beta of 1.36. The business has a fifty day moving average price of $10.72 and a 200 day moving average price of $7.83.

Artelo Biosciences (NASDAQ:ARTL) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($3.54). On average, research analysts anticipate that Artelo Biosciences will post -2.62 earnings per share for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.